Topical Treatment of Infantile Hemangiomas – Where Are We Now? / Topikalni tretman infantilnih hemangioma – gde smo danas?

1. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo, JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51.10.1056/NEJMc0708819Search in Google Scholar

2. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010;163:269-74.10.1111/j.1365-2133.2010.09848.xSearch in Google Scholar

3. Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol 2010;146:564-5.10.1001/archdermatol.2010.67Search in Google Scholar

4. Ni N, Langer P, Wagner R, Guo S. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol 2011;129:377-9.10.1001/archophthalmol.2011.24Search in Google Scholar

5. Blatt J, Morrell DS, Buck S, Zdanski C, Gold S, Stavas J, et al. {beta}-Blockers for Infantile Hemangiomas: A Single-Institution Experience. Clin Pediatr (Phila) 2011;50:757-63.10.1177/0009922811405517Search in Google Scholar

6. Chakkittakandiyil A, Phillips R, Frieden IJ, Siegfried E, Lara- Corrales I, Lam J, et al. Timolol Maleate 0.5% or 0.1% Gel- Forming Solution for Infantile Hemangiomas: A Retrospective, Multicenter, Cohort Study. Pediatr Dermatol. 2011; [Epub ahead of print].10.1111/j.1525-1470.2011.01664.xSearch in Google Scholar

7. Volotinen M, Hakkola J, Pelkonen O, Vapaatalo H, Maenpaa J. Metabolism of ophthalmic timolol: new aspects of an olddrug. Basic Clin Pharmacol Toxicol 2011;108:297-303.10.1111/j.1742-7843.2011.00694.xSearch in Google Scholar

8. Zimmerman TJ, Kooner KS, Morgan KS. Safety and efficacy of timolol in pediatric glaucoma. Surv Ophthalmol 1983;28:262-4.10.1016/0039-6257(83)90145-5Search in Google Scholar

9. Kubota K, Yamada T, Kikuchi K, Koyama E, Ishizaki T. Pharmacokinetics and beta-blocking effects of transdermal timolol. Eur J Clin Pharmacol 1993;44:493-5.10.1007/BF003155518359190Search in Google Scholar

10. Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010;128:255-6.10.1001/archophthalmol.2009.37020142555Search in Google Scholar

11. O’Loughlin A, O’Donnell B, Watson R. Mature infantile haemangiomas role for propranolol. J Eur Acad Dermatol Venereol 2010;25:1363-4.10.1111/j.1468-3083.2010.03915.x21108669Search in Google Scholar

12. Khunger N, Pahwa M. Dramatic response to topical timolol lotion of a large hemifacial infantile haemangioma associated with PHACE syndrome. Br J Dermatol 2011;164:886-8.10.1111/j.1365-2133.2010.10177.x21158749Search in Google Scholar

13. K, Kunzi-Rapp. Topical Propranolol Therapy for Infantile Hemangiomas. Pediatr Dermatol 2011; [Epub ahead of print].10.1111/j.1525-1470.2011.01615.x22141326Search in Google Scholar

14. Ademola JI, Chow CA, Wester RC, Maibach HI. Metabolism of propranolol during percutaneous absorption in human skin. J Pharm Sci 1993;82:767-70.10.1002/jps.26008208028377110Search in Google Scholar

15. Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. Interactions between novel terpenes and main components of rat and human skin: mechanistic view for transdermal delivery of propranolol hydrochloride. Curr Drug Deliv 2011;8:213-24.10.2174/15672011179447990721235472Search in Google Scholar

16. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol 2003;139:1347-50.10.1001/archderm.139.10.134714568839Search in Google Scholar

17. Sidbury R, Neuschler N, Neuschler E, Sun P, Wang XQ, Miller R, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003;121:1205-9.10.1046/j.1523-1747.2003.12521.x14708627Search in Google Scholar

18. Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, Wessels MR. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 2004;173:4627-4.10.4049/jimmunol.173.7.462715383597Search in Google Scholar

19. Martinez MI, Sanchez-Carpintero I, North Pe, Mihm MC. Infantile haemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002;138:881-4.10.1001/archderm.138.7.88112071813Search in Google Scholar

20. Ho NTC, Lansang P, Pope E. Topical imiquimod in the treatment of infantile haemangiomas: A retrospective study. J Am Acad Dermatol 2007;56:63-8.10.1016/j.jaad.2006.06.01117190622Search in Google Scholar

21. McCuaig CC, Dubois J, Powell J, Belleville C, David M, Rousseau E, et al. A Phase II, Open-Label Study of the Efficacyand Safety of Imiquimod in the Treatment of Superficial and Mixed Infantile Hemangioma. Pediatr Dermatol 2009;26:203-12.10.1111/j.1525-1470.2008.00857.xSearch in Google Scholar

22. Welsh O, Olazaran Z, Gomez M, Salas J, Berman B. Treatment of infantile haemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 2004;51:639-42.10.1016/j.jaad.2004.04.022Search in Google Scholar

23. Barry RBM, Hughes BR, Cook LJ. Involution of infantile haemangiomas after imiquimod 5% cream. Clin Exp Dermatol 2008;33:446-9.10.1111/j.1365-2230.2007.02676.xSearch in Google Scholar

24. Jiang C, Hu X, Ma G, Chen D, Jin Y, Chen H, et al. A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma. Pediatr Dermatol. 2011;28:259-66.10.1111/j.1525-1470.2011.01520.xSearch in Google Scholar

25. Myhre PE, Levy ML, Eichenfield LF, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children. Pediatr Dermatol 2008;25:88-95.10.1111/j.1525-1470.2007.00590.xSearch in Google Scholar

26. Hussain W, Judge MR. The role of imiquimod in treating infantile haemangiomas: cause for concern? Clin Exp Dermatol 2009;34:e257.10.1111/j.1365-2230.2008.03151.xSearch in Google Scholar

27. Elsas FJ, Lewis AR. Topical treatment of periocular capillary hemangioma. J Pediatr Ophthalmol Strabismus. 1994;31:153-6.10.3928/0191-3913-19940501-06Search in Google Scholar

28. Cruz OA, Zarnegar SR, Myers SE. Treatment of periocular capillary hemangioma with topical clobetasol propionate. Ophthalmology 1995;102:2012-5.10.1016/S0161-6420(95)30762-2Search in Google Scholar

29. Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol 2005;52:281-6.10.1016/j.jaad.2004.09.00415692474Search in Google Scholar

30. Pandey A, Gangopadhyay AN, Sharma SP, Kumar V, Gupta DK, Gopal SC. Evaluation of topical steroids in the treatment of superficial hemangioma. Skinmed 2010;8:9-11.Search in Google Scholar

31. Greenberger S, Adini I, Boscolo E, Mulliken JB, Bischoff J. Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 2010;13:327-35.10.1007/s10456-010-9189-6303438820872175Search in Google Scholar

32. Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Corticosteroid suppression of VEGF-A in infantile hemangiomaderived stem cells. N Engl J Med 2010;362:1005-13.10.1056/NEJMoa0903036284592420237346Search in Google Scholar

33. Sugarman JL, Mauro TM, Frieden IJ. Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor. Arch Dermatol 2002;138:314-6.10.1001/archderm.138.3.31411902979Search in Google Scholar

34. Metz BJ, Rubenstein MC, Levy ML, Metry DW. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 2004;140:867-70.10.1001/archderm.140.7.86715262700Search in Google Scholar

35. Frieden IJ. Addendum: Commentary on becaplermin gel (Regranex) for hemangiomas. Pediatr Dermatol 2008;25:590.10.1111/j.1525-1470.2008.00781_3.x19067861Search in Google Scholar